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ANALYSIS OF THE CURRENT RECOMMENDATIONS FOR 
PHARMACOLOGIC INTERVENTIONS AND LIFESTYLE MODIFICATIONS 
FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME 
KRISTEN HASEROT  
ABSTRACT 
 Polycystic ovarian syndrome (PCOS) is the most prevalent female endocrine 
disorder affecting between 5-15% of women. Characterized by a combination of 
polycystic ovaries, androgen excess, and abnormal ovulation, untreated PCOS may 
progress to metabolic abnormalities and increase the risk of adverse health outcomes. 
Adult PCOS is evaluated using the Rotterdam Consensus Criteria, which requires two of 
three clinical findings. PCOS is a condition of exclusion, and it is essential to consider 
differential pathologies before diagnosis. 
           PCOS is a heterogeneous condition, and treatment is fitted to the symptoms that 
each individual experiences. The physiological effects of PCOS present during puberty, 
typically around the average age of menarche. The exact etiology of PCOS is unknown, 
and preventing and curing the condition is not yet possible. Metabolic disturbances 
caused by PCOS, including insulin resistance and increased blood glucose level, are 
treated with similar methods as diabetes type 2. Insulin sensitizing agents are used to treat 
insulin resistance caused by PCOS. The primary treatment for insulin resistance in this 
population is metformin (Glucophage) due to its relatively safe use and effectiveness in 
normalizing insulin sensitivity and assisting with normalizing weight. 
The correlation of PCOS with insulin resistance, central obesity, and metabolic 
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syndrome highlights the importance of diet and exercise supplementation for this 
population. Weight loss of only 5% in obese and overweight PCOS patients can 
significantly improve PCOS symptoms, including insulin resistance, androgen levels, and 
fertility. Exercise alone helps increase the sensitivity of skeletal muscle to insulin and 
decreases metabolic syndrome risk.   
The effect of PCOS on the hypothalamic-pituitary-gonadal axis can be 
detrimental to ovulation and implantation of a fertilized egg. Treatments that suppress the 
HPG-axis cannot be continued during attempts to become pregnant and throughout 
pregnancy. Ovulation-inducing agents can improve the rate of ovulation and increase 
fertility; however, some women may become resistant to these treatments. Clomiphene 
citrate (Clomid) is often the primary drug used to induce ovulation; however, 
monotherapy with letrozole has shown greater improvements in pregnancy and live birth 
rates. Gonadotropins may also be successful treatments, but there is an accompanied 
increased risk of ovarian hypersensitivity syndrome and multiple pregnancies. 
Laparoscopic ovarian drilling may help decrease androgen production in the ovary and 
briefly increase pregnancy capability. During pregnancy, metformin may help decrease 
the risk of gestational diabetes; however, the long-term effect of fetal exposure to 
metformin is not well studied. 
Cosmetic symptoms of PCOS, including hirsutism and acne vulgaris, may cause 
severe social stress. PCOS women are at additional risk of depression and anxiety. 
Cosmetic and mental health concerns, combined with the stress caused by the high 
prevalence of infertility in PCOS, highlight the need for psychological help to be 
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considered in improving the overall quality of life. Combining cognitive behavioral 
therapy with treatments may help PCOS women maintain treatment and improve their 
quality of life. 
The most effective treatment may require modification throughout a patient’s life 
due to the variance in gonadocorticoid levels throughout a female’s life. Post-menopausal 
women continue to have excess androgens and estrogens in circulation. High levels of 
ovarian and adrenal production of gonadocorticoids combined with decreased circulating 
binding globulins can lead to stress on the metabolic and cardiovascular systems in PCOS 
after menopause. Continuous levels of increased triglycerides increase the risk for 
atherosclerosis and adverse cardiac events. PCOS women have an increased risk of 
endometrial and ovarian cancer, while a link between breast cancer and PCOS is widely 
disputed. There is 1.66 times higher risk for cardiovascular events, including 1.96 times 
greater risk for stroke in women with PCOS compared to non-PCOS women when 
controlled for weight. 
           As we begin to understand the increased risk factors for hypertension, 
hyperlipidemia, and cardiovascular stress with PCOS, it is crucial to understand how to 
diagnose and treat PCOS patients in the early stages of the disorder. Irregularities in 
typical puberty and menarche in adolescents increase the difficulty of diagnosis and may 
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 Polycystic ovarian syndrome (PCOS) is an endocrine disorder with a combination 
of symptoms, including cysts that form abnormally within female ovaries, androgen 
excess, and chronic anovulation. PCOS is the most prevalent endocrine pathology for 
reproductive-age females, affecting between 5–15% of females depending on the 
diagnostic reporting method used (Rasquin Leon & Mayrin, 2020). While some of the 
symptoms associated with PCOS are directly related to the reproductive system, the 
complex hormonal disturbances often lead to pathologies in other organ systems. Proper 
PCOS diagnosis requires excluding other conditions that share similar hyperandrogenism 
and hyperinsulinemia pathologies due to the condition's broad definitions. Women with 
PCOS have a higher incidence rate of obesity which compounds the adverse side effects 
of PCOS.  This thesis will explore the pharmaceutical and lifestyle recommendations 
used to treat the systemic effects of PCOS. Due to significant hormonal and physiological 
changes throughout sexual development in females, we will consider treatment for 
multiple age groups and their unique challenges stemming from PCOS. 
Hypothalamic-Pituitary-Gonadal Axis 
The hypothalamus integrates neurological and hormonal signals stemming from 
throughout the human body and serves as the control center for homeostasis through 
endocrine signaling. The hypothalamic-pituitary-gonadal axis (HPG-Axis) is responsible 
for the maintenance and maturation of the female reproductive system. Based on 
circulating levels of gonadal hormones, the hypothalamus secretes or inhibits the 
secretion of gonadotropin releasing hormone (GnRH) to the anterior pituitary gland via 
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the hypophyseal portal circulation. GnRH stimulates the gonadotropic cells to release 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) into the systemic 
circulation (Casteel & Singh, 2020). Fluctuating LH and FSH levels target the uterus and 
ovaries to regulate the release of gonadocorticoids and progesterone in reproductive-age 
females. The hormones released by the ovaries, including gonadocorticoids (estrogen and 
androgen) and progesterone, are essential for controlling the menstrual cycle and 
pregnancy. Estrogens are a group of hormones that include estrone (E1), estradiol (E2), 
estriol (E3), and esterol (E4). The ovaries produce E2, the most potent estrogen, and the 
most abundant estrogen in reproductive-age females (Hariri & Rehman, 2020). 
Androgens are a group of hormones including testosterone, dihydrotestosterone (DHT), 
dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEAS). 
Negative feedback loops in the HPG Axis prevent the over-production of estrogen 
by the ovaries. The circulating levels of estrogen and androgen directly inhibit the HPG-
Axis in two ways. First, both gonadocorticoids inhibit GnRH secretion from the 
hypothalamus. Second, the gonadocorticoids antagonize the gonadotrophic cells in the 
anterior pituitary. These targets lead to decreased LH and FSH release into circulation 
and a subsequent decrease in estrogen and progesterone production by the ovaries (See 
Figure 1). Therefore, increasing the concentration of circulating estrogen activates the 
negative feedback loops and causes a decrease in androgen and estrogen production from 




Figure 1: Hypothalamic-Pituitary-Gonadal Axis: Green lines represent stimulation and red 
lines represent the end products (estrogen and progesterone) inhibiting the HPG-axis at 
multiple levels (Adapted from Emanuele & Wezeman, 2003). 
PCOS is commonly characterized by an abnormal excess of androgen in 
circulation. Of the androgens, only DHT and testosterone stimulate the androgen receptor 
(Goldman et al., 2017). Therefore, of the androgens, only the free circulating DHT and 
testosterone affect the target organs. The connection between the HPG-axis and the 
synthesis of androgens and estrogens is required to understand PCOS treatment targets. 
Androgens and estrogens are steroids derived from a cholesterol base. Cholesterol is 
converted into pregnenolone, pregnenolone is converted to 17-α-hydroxypregnenolone, 
and then hydroxypregnenolone is converted into DHEA. The androgen androstenedione 
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is a precursor for all estrogens. The enzyme aromatase irreversibly demethylates 
androstenedione and testosterone into estrogens (Blakemore & Naftolin, 2016). 
Testosterone can also be converted into dihydrotestosterone, the more potent androgen, 
by the enzyme 5-α-hydroxylase (see Figure 2). The amount of estrogen produced depends 
on the presence and levels of androgen combined with the aromatase enzyme activity. 
The production of aromatase and ovarian testosterone are discussed in the ovulation 
section. 
 




Estrogens and androgens are synthesized in the ovaries and the zona reticularis 
layer of the adrenal gland (Antoniou-Tsigkos et al., 2019). These gonadocorticoids are 
transported in the blood by the carrier proteins human serum albumin and sex hormone 
binding globulin (SHBG), while progesterone is carried by corticosteroid-binding 
globulin (CBG). When these hormones are not bound to a carrier protein, they are free to 
diffuse across cell membranes and alter cell transcription (Hammond, 2016). Treatment 
of hyperandrogenic serum in PCOS patients may target the HPG-Axis or adrenal gland 
since these are the two sources of androgen synthesis.  
The HPG-Axis is dormant before puberty, excluding a short period in infancy, 
and therefore the physiological effects of PCOS are not seen in prepubertal children 
(Kota & Ejaz, 2020). Although the ovaries do not become an active source of estrogen 
until puberty, maintaining an optimal estrogen level is vital for the function of multiple 
body systems in all age groups. Estrogen from the adrenal gland is an essential factor for 
bone growth and maturation before and during puberty.  In reproductive age women, 
most estrogen in the systemic circulation is synthesized by the ovaries under the direct 
control of the HPG-axis. After menopause, estrogen in circulation is almost entirely from 
the adrenal gland. Estrogen is important in bone growth and maintaining bone mineral 
density, endothelial elasticity, fertility, breast development, and optimal immune function  
(Mauvais-Jarvis et al., 2013). Prolonged exposure to excess estrogen can lead to an 
increased risk of breast, endometrial, and ovarian cancers and thrombosis (Abou-Ismail et 
al., 2020), (Liang & Shang, 2013). Low concentrations of estrogen, commonly seen in 
post-menopausal women, increases the risk of osteoporosis and cardiovascular disease 
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(Naftolin et al., 2019).  
Ovulation 
Under the control of the HPG-axis, normal adult females release a dominant 
follicle, commonly called an egg, from the ovaries approximately every 25-30 days. A 
prolonged menstrual cycle lasting more than 35 days is considered oligomenorrheic, and 
amenorrhea is the lack of a menstrual period (Reed & Carr, 2018). In pubertal 
development, axillary hair growth and thelarche, or breast development, occur 2-3 years 
before menarche (Pediatrics et al., 2006). A 2018 observational study from the Journal of 
Pediatric and Adolescent Gynecology found the average age of menarche in females in 
the United States is 12.25 years (Biro et al., 2018). After a few decades, the estrogen 
produced in the ovary declines, the negative feedback to HPG-axis is removed, and 
increased FSH levels are eventually not able to stimulate enough estrogen to maintain 
ovulation. The average female reaches menopause around age 48 (Shenassa & Rossen, 
2015).  
In reproductive age females, the hypothalamus secretes GnRH in a pulsatile 
manner to stimulate LH and FSH release from the anterior pituitary gland. FSH recruits a 
cohort of primary follicles in the ovary and is important for their initial development. The 
primary follicle is composed of granulosa cells surrounding an oocyte. The FSH 
stimulates aromatase production in the granulosa cells, while LH stimulates 
androstenedione production in the stromal theca cells. The androstenedione will diffuse 
into the granulosa cell, where another enzyme, 17-β-hydroxysteroid dehydrogenase, will 
convert it into testosterone. The increased levels of aromatase will demethylate the 
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testosterone into estradiol (Barbieri, 2014). LH helps to develop the dominant follicle(s) 
further until a surge of LH induces ovulation and the dominant follicle ruptures from the 
ovary (Son et al., 2011). The LH to FSH ratio determines the portion of the 
androstenedione and testosterone that is converted into estrogen. Abnormalities in 
ovarian sensitivity to LH and FSH and abnormal LH/FSH ratio can lead to abnormal 
androgen and estrogen levels. 
After ovulation, the remaining granulosa cells are termed the corpus luteum. The 
corpus luteum is stimulated by LH and produces progesterone. Progesterone inhibits the 
uterus' contraction to allow a fertilized oocyte, the zygote, to implant in the endometrium. 
If the oocyte is fertilized and implanted, the endometrium will release human chorionic 
gonadotropin (hCG). The hCG helps induce angiogenesis to the corpus luteum and 
allows the cells to receive nutrition and continue producing progesterone. Without 
implantation, the Corpus Luteum will not have a sufficient blood supply for nutrition. 
The cells will undergo apoptosis, and the structure will regress into the Corpus Albicans, 
an involution on the ovary. The remaining cohort of primary follicles undergoes follicular 
atresia, a controlled apoptotic mechanism that breaks down the follicles not selected for 
ovulation (Zhou et al., 2019). The follicles' apoptosis causes estrogen levels to decline, 
which removes the negative feedback to the HPG-axis rapidly, and the ovarian cycle 
begins again (see Figure 3). The changes in LH, FSH, and estrogen levels are also crucial 




Figure 3: Hormone Changes Induce Ovulation and Menstruation (Taken from Isometrik, 
2009) 
The endometrium changes in response to hormones that regulate menstruation. In 
the proliferative phase of menstruation, rising estrogen levels stimulate endometrial 
proliferation. The release of the egg from the ovary increases progesterone levels and 
initiates the secretory phase of menstruation. Progesterone dampens the degree of 
proliferation by estrogen, promotes the formation of secretory glands, and inhibits the 
myometrium from contracting (Bethesda, 2020). When the corpus luteum regresses, 
progesterone levels fall, the uterus contracts, and menstruation occurs. Women with 
PCOS have high estrogen levels; however, the dysregulation of the HPG-Axis causes 
abnormal ovulation. If the corpus luteum does not form, as a result of anovulation, 
progesterone synthesis is impeded. Estrogen unopposed by progesterone increases 
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endometrial proliferation, and combined with the loss of the shedding of the 
endometrium through menstruation, and the lining grows into endometrial hyperplasia 
(Singh & Puckett, 2020).  In PCOS, as progesterone regulation is removed, the control of 
endometrial proliferation is hindered, increasing the risk for endometrial cancer. 
In a polycystic ovary, many benign cysts are found in and on the ovary's cortex. 
The cysts, known as functional cysts, may stem from problems during follicular atresia 
and corpus luteal resorption (Ovarian Cysts, 2017). Although a polycystic ovary is not 
required for or by itself wholly indicative of PCOS, it is a common finding. A diagnosis 
of a polycystic ovary is made through a transvaginal ultrasound. Some women with 
polycystic ovaries experience intense pain, and others may have little to no discomfort. 
Often, the cysts resolve without treatment; however, laparoscopic surgery can aspirate the 
cyst. In extreme cases, an oophorectomy is performed to remove the ovaries altogether  
(Pathmanathan et al., 2020).  
Figure 4: PCOS Histology-PCOS modeled in a rat ovary (Taken from Alahmadi et al., 
2020) 





The American College of Obstetricians and Gynecologists currently recommends 
using the Rotterdam Consensus Criteria to diagnose PCOS. Other assessment methods 
are the National Institutes of Health Criteria 1990 and Androgen Excess Society 2006, 
shown in the table below. The Rotterdam Consensus Criteria requires two of the 
following symptoms: hyperandrogenism, oligomenorrhea/amenorrhea, and polycystic 
ovaries confirmed by ultrasound.  
Table 1: Diagnostic Criteria Methods for PCOS (Adapted from “ACOG Practice Bulletin 
No. 194,” 2018) 
Signs and Symptoms 
National Institutes 







Hyperandrogenism Required Not Required Required 
Oligomenorrhea or 















and one other 
sign/symptom 
*= current diagnostic method used 
The Rotterdam Criteria allows for more inclusion of patients than the original 
National Institutes of Health Criteria and the more recently introduced Androgen Excess 
Society criteria. The Androgen Excess Society criteria excludes patients that don’t 
present with hyperandrogenism. PCOS patients without hyperandrogenism show no 
statistical difference in their abnormal LH to FSH ratio with exposure to exogenous 
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GnRH administration than those who are hyperandrogenemia (Lewandowski et al., 
2011). Therefore, the broadness of the Rotterdam criteria remains the best diagnostic 
method and this thesis will focus on the treatment of PCOS diagnosed by the Rotterdam 
criteria.  
The Rotterdam criteria initially required a minimum of 12 follicles ranging from 2 
to 9 nm on a single ovary or an enlarged ovary measuring greater than 10 mL. As 
diagnostic techniques have improved, the definition of polycystic ovaries has been 
updated. The use of transabdominal ultrasounds does not provide the detail and accuracy 
of a transvaginal ultrasound. The transvaginal ultrasound avoids interference from the 
bladder and fat since the vagina is closer than the abdominal wall to the ovaries (Balen et 
al., 2003). The American Endocrine Society now suggests using a transvaginal ultrasound 
with a minimum of 25 follicles ranging from 2 to 9 nm or a single ovary greater than 10 
mL to diagnose a polycystic ovary (Goodman et al., 2015).  
The range of PCOS symptoms includes cosmetic disorders such as hirsutism and 
acne to more severe conditions such as insulin insensitivity and hypertension. Women 
may also experience psychological conditions such as increased anxiety and depression 
(Mehrabadi et al., 2020). Significant symptoms associated with PCOS are unpredictable 
ovulation, infertility, and metabolic syndrome. The advancement of the symptoms may 
lead to irreversible damage to the cardiovascular system and metabolic regulation. 
Prolonged PCOS without treatment can lead to life-threatening secondary conditions, 
including diabetes type 2, hypertension, and cardiovascular disease. The stigma 
associated with weight gain and hirsutism, increased difficulty becoming pregnant, and 
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menstrual irregularity observed with PCOS may lead to decreased life quality  
(Chaudhari et al., 2018).  
Table 2: Frequency of associated symptoms (Taken from Bednarska & Siejka, 2017) 
 
According to Bednarska and Siejka, 40% of women diagnosed with PCOS have 
associated Metabolic Syndrome (Table 2). Metabolic syndrome is a complex 
physiological state with a clinical presentation including three of the following risk 
factors: abdominal obesity, hypertension, elevated fasting plasma glucose, elevated 
triglyceride levels, and decreased high-density lipoprotein levels (Samson & Garber, 
2014). Metabolic syndrome imposes a two-fold increase in adverse cardiac events and a 
1.5 fold increase in mortality overall (Mottillo et al., 2010).  Due to the high prevalence 
of Metabolic Syndrome in PCOS patients, the monitoring of metabolic regulation is 
necessary for the lifelong management of PCOS.   
Insulin resistance is a key part of Metabolic Syndrome and, if untreated, may 
progress to diabetes type 2. Insulin is required to facilitate the uptake of circulating 
glucose and maintain blood glucose level (BGL) at an optimal concentration. Insulin is a 
peptide produced by pancreatic β-cells in response to increased BGL. Blood exiting the 
digestive tract tissues is sampled by the pancreas, an organ sensitive to fluctuations in 
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glucose. Glucose enters the β-cells in the pancreatic Islets of Langerhans through the 
GLUT-1 and GLUT-3 transporters (McCulloch et al., 2011). Inside the pancreatic β-cells, 
the glucose is phosphorylated, the phosphorylated glucose inhibits a potassium channel, 
depolarizing the cell membrane. This depolarization induces the opening of a voltage-
gated calcium channel, calcium enters the cell, and insulin is secreted from the cell into 
circulation. 
Insulin travels freely through the circulation to target tissues without a carrier 
protein. The insulin receptor is a receptor tyrosine kinase that activates a phosphorylation 
cascade, leading to a vesicle's translocation containing GLUT-4 receptors to the cell 
surface. The localization of GLUT-4 receptors to the cell membrane allows glucose in the 
blood to enter skeletal muscle, cardiac muscle, and fat for metabolism and storage (Leto 
& Saltiel, 2012). When glucose is allowed to enter cells, the circulating BGL drops as the 
cell utilizes glucose in glycolysis and oxidative phosphorylation or stores it as glycogen. 
The insulin receptors can be desensitized if high amounts of insulin overstimulate them. 
When circulating insulin levels become less effective in helping glucose enter the cells, 
the beta cells compensate by releasing increasing amounts of insulin to maintain 
homeostasis (Rorsman & Braun, 2013). Eventually, the insulin receptors become highly 
resistant to the effects of insulin, even at high insulin levels, and the circulating blood 
glucose levels rise. Hyperglycemia induced insulin insensitivity is the etiology of 
diabetes type 2, a common consequence of obesity. However, it is essential to note that 
increased insulin resistance and metabolic syndrome are common in obese and non-obese 
women with PCOS (Lisa J. Moran et al., 2010). 
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Insulin and Insulin-like growth factor 1 (IGF-1) have been shown to potentiate the 
LH production of androgen in the theca cell (see Figure 5). Hyperandrogenemia inhibits 
the release of GnRH and causes low levels of LH and FSH in circulation. In patients with 
hyperinsulinemia caused by insulin resistance, the ovarian insulin receptor is not 
desensitized. The increased circulating insulin helps potentiate androgen production in 
the ovary even with low LH levels caused by negative feedback to the HPG-Axis 
(Rosenfield, 2001). As the theca cells continue to produce androstenedione, androgen 
levels rise. The lack of FSH caused by the inhibited HPG-axis fails to synthesize 
significant aromatase, and increasing androgen production exceeds the aromatase's 
activity level, increasing androgens more significantly than estradiol.    
 
Figure 5: The effect on Insulin and IGF-1 on LH sensitivity (Taken from Rosenfield, 2001) 
Two of the methods used to evaluate insulin resistance are an oral glucose 
tolerance test (OGTT) and the homeostatic model assessment of insulin resistance 
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(HOMA IR). The OGTT measures BGL after a glucose load is given and determines the 
body's ability to maintain homeostasis by measuring how quickly BGL returns to normal 
(Khan et al., 2019). OGTT is clinically used to diagnose diabetes type 2. HOMA IR is a 
mathematical prediction of how well the body reacts to glucose-based off circulating 
glucose and insulin levels (Tang et al., 2015). Both will be used in the studies in this 
thesis to evaluate insulin sensitivity.  Hemoglobin A1c (HbA1c) test assesses the fraction 
of blood's glycated hemoglobin, an indicator of the average range of circulating glucose 
levels for the past 2–3 months (Radin, 2014). 
Hirsutism is abnormal hair growth in females. Treatment options for this include 
shaving, topical creams, laser hair removal, and androgen regulation through methods we 
will discuss later in this thesis (Spritzer et al., 2016).  Hair growth is dependent on 
stimulation of the pilosebaceous unit. During adrenarche, androgens from the adrenal 
gland initiate the growth of axillary and public hair. In most hirsutism cases, increased 
androgen levels or sensitivity after puberty stimulate hair growth in androgen-sensitive 
areas, typically associated with masculinity (Mofid et al., 2008). Increased DHT and 
testosterone levels in many PCOS females cause increased stimulation of the androgen 
receptor on the pilosebaceous unit (W.-C. Chen & Zouboulis, 2009). Androgens also 
increase the thickness and length of the hair and lead to adrenergic alopecia (Randall, 
2008). The extent of hirsutism has been directly linked to the severity of insulin 
resistance and hyperinsulinemia. Increased total testosterone and insulin levels show a 
synergistic effect on masculine hair growth (Landay et al., 2009).  
Infertility and anovulation can be linked to increased androgen levels, drastically 
 
16 
inhibiting the HPG-Axis. The low levels of circulating FSH in PCOS are insufficient to 
recruit and nurture a cohort of primary follicles in the ovary. Increased LH to FSH ratio 
and increased LH sensitivity both increase androgen production. Aromatase synthesis is 
not stimulated, and estrogen levels do not increase. A dominant follicle is not ovulated, 
and the corpus luteum does not form, so progesterone is not released. Estrogen and 
progesterone are required for the endometrial lining to build during the proliferative 
phase of menstruation.  Without the cyclic patterns of hormone signaling through 
ovulation, the maintenance and preparation of the endometrium for implantation is 
inhibited, and menstruation ceases. 
Risk Factors  
The etiology of PCOS still remains mostly unknown. Risk factors including 
genetic polymorphisms and obesity may increase a women’s likelihood of a PCOS 
diagnosis. Due to the complex interactions between PCOS with insulin sensitivity and 
hyperandrogenism, a definitive cause-and-effect is unknown, and the syndrome is likely 
from heterogenous origins (Witchel et al., 2020). 
Changes to the concentration of circulating SHBG inversely affect the 
concentration of free circulating androgens and estrogens. According to the free hormone 
hypothesis, steroid hormones (including estrogen and androgen) can only enter cells 
when they are not bound to a binding globulin (Keevil & Adaway, 2019). SHBG is 
synthesized in the liver under the control of the transcription factor HNF-4 α.  HNF-4 α is 
downregulated individually in conditions including obesity, hyperandrogenism, and 
insulin resistance (Zhu et al., 2019). The levels of SHBG correlate with insulin resistance, 
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and as increased resistance lowers the circulating SHBG, more androgens and estrogens 
are free to enter cells and modulate cell transcription (Feng et al., 2019). 
Conditions involving increased androgen levels or increased insulin resistance 
have a synergistic effect on circulating androgens and insulin insensitivity. 
Hyperandrogenemia correlates with increased fasting blood glucose levels in mice 
(Chunlin et al., 2017). Insulin resistance is linked to increased androgens produced by 
theca cells (Qu et al., 2009). This bidirectional connection between the two symptoms of 
PCOS makes targeting an exact source of the dysfunction difficult. Each side effect also 
exacerbates the other, making PCOS a progressive condition. 
Approximately 10% of women with PCOS also have a diabetes type two 
diagnosis. Untreated diabetes type 2 and uncontrolled BGLs lead to dysfunction in the 
body’s microvasculature. The increased glucose in circulation for extended time periods 
increases inflammation and increases vasculature stiffness causing irreversible 
retinopathy and nephropathy over time (J. Xu et al., 2018). Complications as a result of 
impaired circulation in diabetes type two are also a common cause of amputation.  A 
2019 study found that diabetes type two contributed to 81.8% of lower limb amputations 
between 2005 and 2016 (Hussain et al., 2019).  With increasing diabetes mellitus cases in 
the US, the prevalence of diabetes-related amputation in 2005 is expected to double by 
2050 (Ziegler-Graham et al., 2008). 
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Age Differences in Women 
The treatment of PCOS various depending on age and life-goals for the patient. It 
is crucial to consider if females want to conceive children considering many treatment 
methods involve inhibiting gonadocorticoid production in the ovaries, therefore inhibiting 
ovulation. When women enter menopause, the primary source of estrogen and androgen 
production switches from the ovaries to the adrenal gland. The result is that treatments 
that target the HPG-Axis may no longer be as effective. The associated comorbidities 
with PCOS become more exacerbated in post-menopausal women.  
History of PCOS Treatment: 
Irving Freiler Stein and Michael Leventhal discovered PCOS after studying 
infertility and hirsutism in females around 1930. Using radiology, the physicians 
observed cysts on the ovaries and performed ovarian wedging to remove sections of the 
ovary. In 1935, Stein and Leventhal published the study “Amenorrhea associated with 
polycystic ovaries,” which has become the foundation for modern PCOS research. 
Originally termed Stein-Leventhal Syndrome, PCOS publications in the 65 years 
following Stein and Leventhal’s publication were meager. From 1950 to 2000, there were 
approximately 8,000 articles published, however between 2001 and 2015, there were 
more than eight times as many publications regarding PCOS (Azziz & Adashi, 2016).  
PCOS remains a highly variable condition among those affected and is currently a 
diagnosis of exclusion because there are many other pathologies with similar 
presentations. The presence of hyperandrogenic tumors, adrenal hyperplasia, 
hyperprolactinemia, and other known sources of hyperandrogenism are disqualified from 
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A single-focused treatment has not been discovered for the management of PCOS. 
Treatment of PCOS is focused on the individual's specific presentation and treating the 
dysregulation of the affected organ system(s) because of the wide range of symptoms 
women experience. Due to the compounding effects of PCOS, multiple treatment 
methods may be required along with lifelong monitoring and modifications. The typical 
treatment methods focus on decreasing insulin resistance, stabilizing androgen levels, and 
decreasing metabolic syndrome risk factors. Non-pharmaceutical treatments, including 
exercise, weight loss, dietary improvements, and supplementation with cognitive 
behavioral therapy also reduce the severity of PCOS symptoms. 
Pharmacological Treatments- Insulin Sensitizers 
The first-line treatment for insulin resistance in PCOS is insulin sensitizers. 
Insulin sensitizers are divided into two categories: biguanides (metformin) and 
thiazolidinediones (rosiglitazone and pioglitazone). Treatment with insulin sensitizers is 
dependent on the functioning of the pancreatic beta cells since the efficacy of insulin 
sensitizers are dependent on the presence of insulin initiating glucose entry into 
peripheral tissues. If the beta cells no longer produce insulin, exogenous insulin must be 
administered to maintain BGL. Common to PCOS, hyperinsulinemia leads to diminishing 
insulin receptor sensitivity due to overstimulation of the receptor (Hudish et al., 2019). 
Insulin resistance prolongs the time for glucose to be internalized into cells and BGL will 
remain high after the course of a meal. If the beta cells are overstimulated and forced to 
produce high amounts for an extended period, they become exhausted and lose their 
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ability to produce insulin (Boland et al., 2017).  
Metformin (Glucophage) is the first medication prescribed to treat insulin 
resistance in women with PCOS. It is also a secondary treatment for pregnancy initiation, 
which will be discussed further later in this thesis. Although the complete mechanism is 
unknown, the significant tissues that accumulate metformin are the intestines, kidneys, 
and liver (G. S. Wang & Hoyte, 2019). Metformin increases insulin receptor sensitivity in 
the liver by inhibiting the mitochondrial electron transport chain at Complex I and 
decreasing ATP production. The decreased ratio of ATP to ADP and AMP activates 
AMP Protein Kinase, a modulator of fatty acid oxidation, and results in the hepatocyte's 
insulin sensitization (Fullerton et al., 2013). Metformin increases intestinal utilization of 
glucose and decreases gluconeogenesis in the liver resulting in decreased glucose 
delivered into the circulation (Rena et al., 2017).  The resulting decreased BGL prevents 
overstimulation of the pancreatic beta-cell, decreases circulating insulin levels, and 
allows the insulin receptor to remain sensitive. 
Metformin is currently the only approved biguanide in the US to treat insulin 
resistance after the other pharmaceuticals on the market were withdrawn for associated 
lactic acidosis. Diabetes type two, which is a result of untreated PCOS, may damage the 
kidneys, and patients with kidney dysfunction may have difficulty clearing metformin. 
Accidental overdosing in PCOS patients may occur if there is associated decreased renal 
clearance, leading to lactic acidosis (Lalau, 2010). Lactic acidosis is only reported in 
about 10 per 100,000 users and metformin treatment is relatively safe (DeFronzo et al., 
2016).  Approximately 25% of patients prescribed metformin report adverse 
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gastrointestinal symptoms, while 5% of patients did not tolerate the drug and discontinue 
treatment (Dujic et al., 2015).  
A three-month longitudinal analysis consisting of the initiation of monotherapy 
with metformin showed significant improvements in fasting BGLs, decreased 
triglycerides, decreased DHEA, and decreased HOMA-IR (Masaeli et al., 2019). A six-
month monotherapy study replicated the Masaeli study results with significant additional 
decreases in BMI, fat percentage, BGL two hours after use, circulating LH, Hba1c levels, 
and free androgen in circulation (Wei et al., 2020). In rats with induced PCOS, metformin 
showed normalization in the LH/FSH ratio, an essential modulator in converting ovarian 
androgen into estrogen (Rencber et al., 2018).  
Thiazolidinediones act as agonists for Peroxisome proliferator-activated receptor 
alpha (PPARY), an important mediator of fatty acid distribution. These drugs increase fat 
storage in adipocytes, decreasing circulating fatty acids and fat storage in skeletal muscle 
and the liver (Nanjan et al., 2018). Lower circulating triglycerides and fatty acids 
contribute to increased peripheral insulin sensitivity (Akbari et al., 2015). PCOS is 
commonly associated with increased central obesity and the mechanism of 
Thiazolidinediones contributes to excess weight gain and exasperation of obesity risk in 
PCOS females (Ross et al., 2011). Thiazolidinediones are currently used as secondary 
treatment methods or in combination with metformin therapy (Zeng et al., 2020). 
Monotherapy with pioglitazone (Actos), has shown more significant improvements in 
menstrual cycle and ovulation cycle lengths than treatment with metformin alone while 
also maintaining similar improvement of free testosterone and DHEA (Y. Xu et al., 
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2017). Although metformin is currently the recommended treatment for PCOS with 
insulin sensitivity, similar improvements make pioglitazone a candidate for patients who 
are intolerant of metformin. 
In a three-month study, the addition of pioglitazone with metformin showed more 
significant decreases in HOMA-IR, IL-6, and IL-8 compared to metformin treatment 
alone (Ali et al., 2019).  IL-6 and IL-8 are proinflammatory biomarkers, and adding 
Pioglitazone to metformin treatment may help treat other pathogenesis of PCOS such as 
atherosclerosis by decreasing systemic inflammation in the body (Tsalamandris et al., 
2018).  
Another mechanism to target hyperandrogenism is spironolactone (CaroSpir, 
Aldactone). Spironolactone is a 5-α-reductase inhibitor and a mineralocorticoid receptor 
antagonist. Decreasing 5-α-reductase activity helps decrease the potent circulating DHEA 
and works as a treatment for hirsutism (J. Brown et al., 2009). In the treatment of PCOS, 
spironolactone is used commonly in a combination treatment which includes a low dose 
of spironolactone, pioglitazone, and metformin (SPIOMET) 
Another emerging treatment for PCOS are inositols. Inositols are precursors for 
the second messenger signaling pathways within cells that regulate FSH and insulin 
secretion. The conversion of myo-inositol into d-chiro-inositol is insulin-dependent, and 
insulin resistance may contribute to decreased signaling in gonadotrophs in the anterior 
pituitary (Genazzani, 2016). Myo-inositol, another insulin sensitizer, has been shown to 
have similar efficacy as metformin for the treatment of insulin sensitivity and amenorrhea 
in women with PCOS (Fruzzetti et al., 2017). Combined inositol treatment required a 
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specific 40:1 ratio of myo-inositol to d-chiro-inositol to maintain the effect of myo-
inositol on improved insulin sensitivity, while the addition of the d-chiro-inositol added 
the additional benefit of improving ovulation  (Nordio et al., 2019).   
Improving insulin sensitivity with these agents may help restore androgen levels 
without directly targeting the HPG-Axis. As discussed earlier, hyperinsulinemia 
decreases circulating SHBG allowing for increased free androgen index. Restoring 
SHBG levels increases the androgens bound to carrier proteins and decreases free 
circulating androgens.  
Pharmacological Treatments- Oral Contraceptives 
Hormonal contraceptives are the first-line treatment for hyperandrogenism 
derived from ovarian overproduction of androgens. Combined hormonal contraceptives 
(COC) typically contain ethinyl-estradiol (EE), a synthetic estrogen, and a progestin. 
These contraceptives are an effective way to regulate the HPG-Axis because estrogen and 
progesterone work at two different levels, the hypothalamus and the gonadotropic cells of 
the anterior pituitary, to inhibit downstream sex hormone production. Estrogen in COCs 
increases circulating SHBG, decreasing the free circulating gonadotropins and reducing 
the action of androgens (Morgante et al., 2020). 
A high LH to FSH ratio is observed in obese and non-obese PCOS women, 
suggesting that regulating the HPG-Axis can help lower circulating androgen levels in 
both groups (Saadia, 2020). A COC containing EE and cyproterone acetate (Diane35) 
caused the reduction of LH and normalization of the LH/FSH ratio in obese and non-
obese participants. The same study also found that combining metformin with the COC 
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increased insulin sensitivity and decreased baseline insulin levels in obese and non-obese 
women while maintaining the reduction in LH/FSH ratio and testosterone levels (Jie et 
al., 2008).    
The treatment of non-obese PCOS women with a COC containing EE and the 
progesterone chlormadinone acetate (Belara) for six months showed improvement in 
acne, hirsutism, circulating testosterone, and androstenedione levels compared to the 
group that did not receive treatment (Uras et al., 2010). A 2018 study monitored 
metabolic risk factors for non-obese PCOS patients with three treatments: COC 
containing EE and drospirenone (Yasmin), metformin, and the COC with metformin, 
against a control group receiving no treatment. The COC treatment alone showed 
increases in HOMA-IR and the metformin treatment group showed decreased HOMA-IR; 
however, the combined treatment group presented with an increased HOMA-IR 
suggesting that metformin supplementation did not combat the adverse metabolic effects 
linked with the COC (Bodur et al., 2018).  
Abnormal adipokine levels, including leptin and ghrelin, are observed in non-
obese PCOS women compared to healthy individuals indicating that normal-weight 
PCOS women are more prone to classically considered “weight linked” diseases such as 
type two diabetes (Lin et al., 2021). Leptin is associated with satiety and is decreased in 
obese women. Adiponectin levels are decreased with hyperandrogenemia and are 
important for glucose sensitivity (Benrick et al., 2017). Ghrelin, the adipokine associated 
with hunger and insulin sensitivity, is lower in PCOS women and is inversely correlated 
with androgen levels (Panidis et al., 2005). The addition of a COC with EE and 
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drospirenone (Yasmin) increased the adipokine Ghrelin but did not affect Leptin levels 
(Sağsöz et al., 2009). When obese PCOS were treated with a COC of EE and cyproterone 
acetate (Diane35), patients experienced an increase in adiponectin levels and 
normalization of adiponectin to leptin ratios not observed in obese PCOS women that 
were treated with metformin (Luque-Ramírez et al., 2009). Females who present with 
metabolic syndrome may also have risk factors for cardiovascular disease, a 
contraindication for COCs which limit their use in this population (E. Brown et al., 
2017). COCs have an increased risk of venous thrombosis and hypertension (Dragoman 
et al., 2018), (Perol et al., 2019). Since PCOS women already have elevated adverse 
cardiovascular risk, the use of COCs may not be indicated for all PCOS women. 
Combining a COC containing EE and norgestimate (Sprintec) with metformin 
caused a more significant reduction in hyperandrogenism than the contraceptive alone but 
did not significantly reduce any other PCOS markers (Cibula et al., 2005). Combining an 
oral contraceptive containing 30 μg of ethinylestradiol and 150 μg of desogestrel 
(Marvelon) with spironolactone was compared with a COC with cyproterone acetate 
(Diane35) on androgen levels and hyperinsulinemia. After three months, the COC with 
spironolactone decreased androstenedione; however, neither treatment improved insulin 
resistance or the free androgen index significantly (Leelaphiwat et al., 2015). The 
beneficial effects of COCs on hyperandrogenemia are more apparent in trials that utilize 
extended treatment use. Another study compared the same COC and spironolactone 
combination for one year and found significant improvement in hirsutism and the levels 
of total and free circulating androgens than metformin alone (Alpañés et al., 2017). 
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Table 3: Treatment with COC and spironolactone compared to metformin (Taken from 
Alpañés et al., 2017) 
 
A six-month study of hyperandrogenemic women with a COC with EE and 
drospirenone (Yaz) found significant increases in SHBG, total testosterone, total 
estradiol, and decreased hirsutism in 78.6% of participants (Caruso et al., 2013). The 
study also measured insulin resistance; however, the participants started with normal 
insulin levels, and no significant change was observed with the addition of the COC. 
Table 4: Treatment with COC in hyperandrogenic females after six months (Taken from 




The effects of an estro-progestin COC compared with spironolactone-
pioglitazone-metformin (SPOIMET) treatment suggest that a treatment that targets the 
metabolic disturbances in PCOS is better at controlling ovulation. A randomized 
controlled study showed that SPIOMET, which targets metabolic abnormalities, was 
significantly better at normalizing insulin, increasing ovulation, and even was more than 
10-fold more effective at normalizing ovulation than the EE and levonorgesterel COC 
(Alesse) (Ibáñez et al., 2020).  90% of the women assigned the SPIOMET drug achieved 
a menstrual regularity return versus only 42% in the oral contraceptive group. PCOS 
women also increase miRNA levels linked to energy homeostasis and control of the cell 
cycle. An analysis of these microRNA, the SPIOMET treatment significantly normalized 
circulating miRNA, while a COC with EE and levonorgestrel (Alesse) did not reduce 
miRNA levels (Díaz et al., 2020).   
Increased androgens and decreased progesterone in untreated PCOS may 
contribute to the almost three-fold increase in endometrial cancer (Haoula et al., 2012). 
The use of COC may decrease endometrial cancer for women with PCOS. Estrogen 
unimpeded by progesterone proliferates the endometrium, and this endometrial 
hyperplasia contributes to a 2.7 fold increase in endometrial cancer risk in PCOS females 
(Chittenden et al., 2009).  This study also found a 2.52 increase in ovarian cancer risk in 
PCOS women and no increase in breast cancer risk. The use of a COC for 4 to 12 years in 
reproductive years decreases this risk by roughly 50%, and there was a continuation of 
decreased risk even after COC treatment was terminated (Hannaford et al., 2007). 
Using a Combined Oral Contraceptive can be an effective and simple treatment 
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for significant decreases in hyperandrogenic symptoms of PCOS. However, with only 
about 5% of 24-year-old women expecting not to conceive children at some point in their 
lives, therapies that allow for and facilitate pregnancy must also be explored (Rybińska & 
Morgan, 2019).  
Nutrition and Exercise  
 Lifestyle modifications, including dietary changes, activity level improvements, 
and cognitive behavioral therapy, have shown beneficial improvements in androgen 
excess, insulin sensitivity, and fertility. Women with PCOS are 1.95 times as likely to be 
overweight and 2.77 times more likely to be obese than women without PCOS (Lim et 
al., 2012). Increases in BMI are associated with exacerbated insulin resistance, 
hyperandrogenism, and decreased fertility. 
 Hypocaloric diets help PCOS patients lose weight; however, a focused high-
protein diet with a low glycemic load lead to better androgen normalization and 
decreased HOMA IR for obese PCOS women (Mehrabani et al., 2012). A 2010 study 
compared the benefits of a low glycemic index diet with a conventional hypocaloric diet 
by measuring insulin sensitivity and controlling weight loss at 7%. While both groups 
showed improvements in OGTT and menstrual cycle regularity, the low glycemic index 
diet showed more significant improvement in both categories with a 95% return of 
normal menstrual cycle in low glycemic index diet versus 63% in the conventional diet 
group. Additional significant improvements were seen in OGTT in the low glycemic 
index group if they were also prescribed metformin (Marsh et al., 2010). This suggests 
that a low glycemic index diet itself and not the weight loss attributed to the improved 
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metabolic and reproductive health with further improvements when combined with 
metformin. Another dietary study followed PCOS women prescribed a glycemic index 
diet that incorporated pulses, or dried legume-oriented seeds with low glycemic indexes, 
including "split peas, green lentils, red split lentils, chickpeas, and pinto, black and 
kidney beans." The pulse diet showed greater normalizations of OGTT, fat levels, and 
diastolic blood pressure reduction than a traditional hypocaloric diet (Kazemi et al., 
2018). 
 Some studies show that simple lifestyle changes can make similar improvements 
to insulin resistance as some prescription medications. The addition of cinnamon powder 
to hyperandrogenic women's diets decreased HOMA-IR and fasting insulin significantly 
compared to the placebo group (Hajimonfarednejad et al., 2018). Compared in two 
randomized groups of PCOS women, the anti-androgen cyproterone acetate (Androcur) 
and phlebotomy showed a statistically similar reduction in HOMA-IR, free androgen 
index, with improved menstrual regularity in about 45% of participants in the 
phlebotomy only group (Behboudi-Gandevani et al., 2019). Treatment with an oral 
contraceptive pill or lifestyle medication improves the perceived quality of life, but 
combining both treatment methods improved excess body hair, BMI, fertility, perceived 
quality of life more than each single treatment alone (Dokras et al., 2016).  
 Diet and exercise have shown promising reductions in PCOS symptoms; 
however, maintaining consistency in a diet and exercise program is difficult. Many 
studies that follow lifestyle modification of PCOS have significant dropout rates. Obese 
PCOS women are more likely to become hungry one hour after a meal than obese 
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controls without any abnormal changes to ghrelin and leptin hunger signaling (Japur et 
al., 2019). The implementation of a high protein diet led to higher fasting ghrelin levels in 
non-PCOS females. However, the diet showed a much less significant increase in ghrelin 
levels and satiety for participants with PCOS (L. J. Moran et al., 2004). Excess 
triglycerides, a classic finding in PCOS, decreases insulin sensitivity in the brain and may 
contribute to inhibited ability to feel full (Banks et al., 2018). The weight-loss drug 
orlistat (Xenical) was shown to help mediate weight loss for women with PCOS while 
improving the HOMA-IR, decreasing circulating androgens, and decreased Metabolic 
Syndrome by 54.4% (Panidis et al., 2014). Exercise alone is enough to increase the 
muscle's sensitivity to insulin, and increased blood flow to skeletal muscle increases 
glucose delivery to tissues and combats some of the insulin resistance (Olver et al., 
2019). 
A community-based study found that women with PCOS were more likely to 
have depression, anxiety, and more significant perceived stress than their counterparts 
with similar socio-demographic status and BMI (Damone et al., 2019). PCOS women 
with elevated HOMA-IR are more than two times as likely to be depressed even when 
adjusted for BMI (Greenwood et al., 2018). Eight weeks of cognitive behavioral therapy 
with no other lifestyle modifications showed significant improvement in women's 
perceived quality of life with PCOS (Abdollahi et al., 2019).  When compared against 
women who tried to lose weight on their own, the group with dietary and nutritional 
advice with cognitive behavioral therapy was seven times more likely to lose 5% of their 




Exercise may also play a psychological role in PCOS patients. A 20-week study 
followed reproductive ability and overall health of overweight and obese PCOS women 
put on three regimens: a hypocaloric diet, a hypocaloric diet with aerobic exercise, and a 
hypocaloric diet and anaerobic resistance exercise. Each of the three groups showed 
similar improvements in reducing blood pressure, fasting insulin and BGL, testosterone, 
and androgen levels, while the exercise groups differed in that they also had decreased 
body fat (Thomson et al., 2008). A 2008 study found that even when PCOS women did 
not decrease their BMI while participating in a 6-month exercise regime, they still had 
significant improvement in their perception of their own body image (Liao et al., 2008). 
The opposite is also true with improvements to mental health increasing weight loss 
results. Women who were given modifications to their diet and exercise lost twice the 
amount of weight on average when attending cognitive behavioral therapy (Cooney et al., 
2018).   
Treatment of Adolescent Age Females 
The age of menarche and consistency of menstrual cycles varies among 
adolescents. Amenorrhea caused by PCOS may be mistaken for delayed puberty, and 
oligomenorrhea may be evaluated as normal fluctuations in the early menstrual cycle 
(Witchel et al., 2015). If an adolescent female does not start her period by age 15 or 
within three years of thelarche, they should be evaluated for causes of amenorrhea, 
including PCOS (Laroche et al., 2013). Adolescent females with PCOS may be 
underdiagnosed because their symptoms are often mistaken for normal puberty. Typical 
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indications of PCOS may be present in unaffected adolescents. With ovarian screening by 
ultrasound, polycystic ovaries and increased ovarian volume is typical in adolescent 
females (Dokras & Witchel, 2014). Ovarian screening of young females is typically is 
performed with a transabdominal ultrasound and can have interference from the bladder 
and fat. A 2018 randomized study found that transvaginal ultrasounds, which are more 
uncommon in adolescents, were better at detecting polycystic ovaries in adolescents' 
PCOS diagnosis  (Youngster et al., 2014).  The variability between adults and adolescents 
with PCOS indicates that the Rotterdam criteria is not a sufficient diagnostic measure for 
adolescents with PCOS. 
Obese and overweight adolescents with PCOS had significant increases in dietary 
energy intake compared with age and BMI-adjusted controls (Hajivandi et al., 2020). One 
year of lifestyle intervention for adolescent PCOS patients resulting in weight loss 
showed significant decreases in testosterone, androstenedione, DHEA-S, while PCOS 
patients who did not alter their weight showed significant estradiol increases (Reinehr et 
al., 2017).  
Oligomenorrhea in adolescence is predictive of risk factors for metabolic 
syndrome and diabetes type two in early adulthood and should be closely monitored 
(Glueck et al., 2015). Recognizing and treating hyperandrogenemia and hyperinsulinemia 
early in the course of PCOS may help to prevent long-term hormonal dysfunction.  
Metformin effectively stabilizes weight and mitigates adolescents' hyperandrogenic 
symptoms (De Leo et al., 2006). In obese adolescents with PCOS ranging from age 12-
22, a low carbohydrate diet led to significant improvements in BMI, waist circumference, 
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and menstrual normality (Ornstein et al., 2011). Improvements to lifestyle, including 
structured exercise and dietary training, led to increases of SHBG levels to 122% of 
baseline, while lifestyle improvements with metformin and a COC containing EE and 
drospirenone (Yasmin) reduced waist circumference, increased SHBG, and decreased 
total testosterone by 55% (Hoeger et al., 2008).  
Women with PCOS also have an increased risk of non-alcoholic fatty liver 
disease than their BMI-matched controls (73.3% versus 46.7%) (Zueff et al., 2012). A 
study followed the use of an estro-progestogen COC (Alesse) with a low dose SPIOMET 
treatment in adolescent girls with a mean age of 15.8 years old. After one year of 
treatment, The SPIOMET treatment showed more significant improvements in insulin 
sensitivity and was the only treatment to show a significant return of regular ovulation 
length while also normalizing the hepatic fat content (Ibáñez et al., 2020).  
Treatment of Reproductive-Age Females (Pregnancy) 
 Women with PCOS have increased difficulty becoming pregnant and risk for 
adverse events throughout the pregnancy. It is estimated that 90% to 95% of women who 
use fertility clinics have PCOS (Teede et al., 2010). The risks involved in pregnancy for a 
mother with PCOS include "gestational diabetes mellitus, preeclampsia, hypertension, 
and small for gestational age babies" (Greger et al., 2020). Females with metabolic 
syndrome in early pregnancy have a 50% chance of complications during the pregnancy 
compared to 33% for women without metabolic syndrome (Grieger et al., 2018).  
Increased circulating insulin and androgens induce changes to the uterus in animal 
models, which may explain the increased difficulty of implantation and pregnancy 
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viability in women with PCOS (Hu et al., 2019). Increased testosterone also affects 
fertility at the level of the fallopian tubes, in addition to ovarian and uterine abnormalities 
(Dulohery et al., 2020).  
Clomiphene citrate (Clomid), letrozole (Femara), and gonadotropins are common 
treatments for unexplained infertility and are commonly used to induce ovulation in 
anovulatory PCOS patients. Clomiphene citrate is typically the primary treatment and 
induces ovulation as a selective estrogen receptor modulator. Letrozole is an aromatase 
inhibitor. Gonadotropins are a group of medications that stimulate the ovary by 
antagonizing the receptors for FSH, LH, or both. In women who become resistant to the 
effects of clomiphene citrate, letrozole, and human menopausal gonadotropin 
(Menotropin) induced similar improvements in clinical pregnancy rate, successful 
pregnancies, and endometrial thickness (Shi et al., 2020).  Gonadotropins are a second 
line treatment since they carry an increased risk of ovarian hyperstimulation syndrome 
(OHSS) and multiple pregnancies.  
Moderate improvements in pregnancy rate and ovulation rate are seen when 
women take insulin sensitizers with clomiphene (Serophene) (Morley et al., 2017). The 
addition of metformin to clomiphene citrate doubled the frequency of regular menstrual 
cycles, ovulation, and conception than clomiphene citrate alone (Tang et al., 2019). In 
clomiphene citrate resistant PCOS women, gonadotropin nearly doubled the likelihood of 
pregnancy between groups from 11.4% to 20.2% (Badawy et al., 2008). 
Aromatase inhibitors are considered for females with hyperandrogenemia that are 
anovulatory. The aromatase enzyme activity is significant in the ovaries, adrenal gland, 
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and adipocytes. The increased concentration of androgens, common in PCOS, are 
demethylated into estrogens which inhibit GnRH, FSH, and LH release and overall 
inhibits the HPG-axis. Aromatase inhibitors, such as the drug letrozole, inhibit the 
aromatase enzyme and decrease the amount of androgen converted to estrogen. This 
removes some of the inhibition from the HPG-axis and can induce ovulation by 
normalizing FSH and LH levels. 
 In a trial that included women with a BMI less than 35, women had a higher 
likelihood of conception when given letrozole over clomiphene citrate, 61% and 43%, 
respectively (Amer et al., 2017). Only 5 mg per day of letrozole during a five-day period 
provided statistically similar results for endometrial thickness, ovulation rate, and 
conception compared to a 100 mg clomiphene citrate per day for five days 
(Zadehmodares et al., 2012).  A 2020 study found letrozole was more effective at 
increasing endometrial thickness, increasing the ovulation rate, and led to more 
pregnancies and live births than the classic treatment of clomiphene citrate (Sakar & 
Oglak, 2020). Compared to clomiphene citrate, letrozole showed increased live birth rates 
(19.1% vs. 27.5%) without increasing the risk for pregnancy loss or multiple births 
(Legro et al., 2014). Treatment with letrozole also corresponded with a greater 
proliferation of the endometrium in the proliferative phase of the menstrual cycle than 
clomiphene citrate treatment resulting in more optimal conditions for implantation (Al‐
Obaidi et al., 2019).  
A combination treatment of clomiphene citrate and letrozole led to more 
significant ovulation induction than letrozole or clomiphene citrate alone, increasing the 
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treatment's effectiveness from 43% to 77% across the two groups (Mejia et al., 2019).  
Letrozole may potentially cause damage to the liver and the ovaries. The addition of 
spironolactone with letrozole in an animal model has been shown to mitigate the common 
side effects of letrozole, including increased uric acids, abnormal weight gain, and 
triglyceride deposits in the liver and ovaries (Adeyanju et al., 2020).  
For women with a BMI ranging between 18.5 and 24.9, the addition of myo-
inositol and folic acid increased the incidence of maturation of a dominant follicle in 
PCOS females who did not initially respond to three increasing doses of letrozole 
(Pourghasem et al., 2019). A combination of metformin and myo-inositol improved 
menstrual cycle length and increased live birth rate compared to women who only were 
given metformin (Agrawal et al., 2019).  Treatment with metformin in pregnancy may 
decrease adverse pregnancy outcomes since exposure in-utero to hyperinsulinemia and 
hyperglycemia is associated with childhood obesity, hypertension, and insulin 
insensitivity (Tam et al., 2017). Animal models exposed to excess testosterone in-utero 
exhibited PCOS-like GnRH patterns (Porter et al., 2019). Although there are benefits to 
metformin use in pregnancy, metformin can cross the placental barrier and be transferred 
through breast milk (Eyal et al., 2010).  
Metformin has been shown to increase ovulation rates in anovulatory and 
oligoovulatory hyperinsulinemic females that are lean, but it is not an effective treatment 
to increase the reproductive potential for females with a BMI over 25 (Önalan et al., 
2005). Three months of pre-treatment with metformin followed by clomiphene increased 
live birth rates (Morin-Papunen et al., 2012). After conception, metformin is prescribed to 
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maintain maternal androgen levels and insulin sensitivity. Women with PCOS are at an 
increased risk of gestational diabetes and type two diabetes induced in pregnancy 
(Kashanian et al., 2008). In a study comparing hyperinsulinemic PCOS pregnancies, the 
use of metformin compared with a control group decreased the risk of miscarriage, 
gestational diabetes, and gestational diabetes with no significant differences in the 
newborn's weight, length, or APGAR scores (De Leo et al., 2011).  Another study also 
found reductions in late miscarriages and preterm birth with the addition of metformin, 
but did not observe a reduction in gestational diabetes (Løvvik et al., 2019). When used 
throughout pregnancy to control hyperandrogenemia, metformin only decreased 
circulating androgens in two PCOS subgroups, non-obese females and PCOS mothers 
carrying a male fetus (Andræ et al., 2020).  
Metformin in pregnancy has not shown increased incidence of congenital defects 
at birth (Gilbert et al., 2006). There is an increased risk of obesity and increased BMI in 
children for mothers with PCOS who were treated with metformin throughout their 
pregnancy. A 2018 study found no significant difference in birth weight between the 
babies of mothers given metformin and those not given metformin. However, the 
metformin group showed increased weight and BMI for the postnatal growth, beginning 
at six months of age and persisting until the trial ended when the children were four years 
old (Hanem et al., 2018). Gestational diabetes increases the mother's risk for gestational 
hypertension and cesarean delivery and the fetus's risk to shoulder dystocia and neonatal 
hypoglycemia (Landon et al., 2009).  Although metformin is proving to be an effective 
treatment for adverse outcomes for pregnant women with PCOS, these studies highlight 
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the importance of monitoring the outcomes for the children. 
Obesity, including in patients without PCOS, is a disruptor of fertility in women 
and increases risk factors for the mother and the fetus. Obese women are three times 
more at risk for infertility than non-obese, are more likely to have poor quality oocytes, 
and have a 40% chance of miscarriage (Silvestris et al., 2018). In obese PCOS patients, 
the first line of treatment is weight loss to increase ovulation. COC, BMI reduction by 
7%, and a combination of the two were compared for pre-treatment of ovulation 
induction with clomiphene citrate in overweight and obese PCOS women. The 
prevalence of metabolic syndrome increased in the COC-only group, while both groups 
that utilized weight reduction methods showed significant increases in ovulation and live 
birth rates that were 2.5 times greater than immediate treatment with clomiphene citrate 
(Legro et al., 2015).  
Laparoscopic ovarian drilling is believed to increase fertility by destroying the 
theca cells in the stroma with heat or a laser, decreasing androgen production. Anti-
mullerian hormone (AMH) is found in high concentrations in PCOS women and is linked 
to ovarian reserve and time between ovulation cycles. Ovarian drilling decreases AMH 
without significantly decreasing ovarian reserve in PCOS women with clomiphene citrate 
resistance (Paramu, 2016). The success of ovarian drilling resulting in a pregnancy is 
comparable to other treatment methods, including aromatase inhibitors and 
gonadotropins, with a decreased risk of OHSS and multiple pregnancies (Farquhar et al., 
2012). Unilateral ovarian drilling significantly increased ovulation rate compared to 
bilateral ovarian drilling (Sunj et al., 2013). In clomiphene-resistant PCOS women, 
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ovarian drilling showed similar improvements to ovulation rate, pregnancies, and live 
births as the ovulation inducing drug tamoxifen (Soltamox) to clomiphene citrate 
(Zakherah et al., 2010).  
Many women struggling to become pregnant will opt for In-Vitro Fertilization 
(IVF).  Due to the strong induction of multiple follicles, multiple pregnancies are 
common. Multiple pregnancy is a pregnancy involving more than one fetus. A 
complication of IVF is OHSS which causes ovarian swelling and excess fluid leaking 
into the abdominal cavity. The incidence of OHSS is higher for PCOS patients. There is 
approximately a 20% chance that a woman with PCOS undergoing IVF will have OHSS. 
However, the use of medroxyprogesterone acetate (Provera) and human menopausal 
gonadotropin decreased the incidence to 0 for 60 women, but further investigation is 
needed for efficacy (Y. Wang et al., 2016). The introduction of myo-inositol and folic 
acid with IVF improved oocyte quality, reduced testosterone levels, and improved 
progesterone levels (Regidor et al., 2018). The supplementation of myo-inositol before 
pregnancy was linked to decreased incidence of gestational diabetes (Crawford et al., 
2015). 
 In vitro maturation (IVM) is an increasing alternative for PCOS pregnancy 
induction to IVF (Julania et al., 2018). Women who opt for IVM have immature oocytes 
removed from their ovaries, and oocytes that are not fully matured are stimulated in a lab 
setting to mature.  Once mature, the oocyte is fertilized by a sperm and transferred into 
the uterus. IVM has a decreased risk for OHSS and is less expensive than classic IVF. 
IVM that is primed with hCG showed similar live birth rates as classic IVF (Ho et al., 
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2018). About 35% of PCOS women had live births following IVM treatment, with better 
outcomes in groups where more eggs were retrieved and higher grade eggs; however, 
maternal age and embryos transferred did not affect pregnancy outcomes (Tannus et al., 
2018) 
Treatment of Post-Menopausal Females 
Estrogen synthesis from the ovaries decreases as a woman nears the end of her 
reproductive age period (see figure 6).  A healthy female in menopause will experience 
an 80-90% decrease in estrogen levels from 40–150pg/mL to 10-20 pg/mL (Gumussoy et 
al., 2020). Estrogen is protective for bones, cardiac tissue, and skeletal muscle. The 
decrease in estrogen in menopause is attributed to decreased bone mineral density, loss of 
control to the genitourinary system, increased cardiovascular events, and sarcopenia 
(Fichera et al., 2013).   
 
Figure 6: Estrogen decline through female adulthood (Taken from Rothmund, 2019) 
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Post-menopausal women with PCOS continue to be hyperandrogenic, with excess 
contributions of androgens from the ovary and adrenal gland (Markopoulos et al., 2011). 
Post-menopausal women with PCOS do not show the typical decrease in estrone as 
normal post-menopausal women, continue to have significantly less SHBG, and an 
increased free androgen index (Schmidt, Brännström, et al., 2011). Although the 
increased levels of circulating estrogen in post-menopausal PCOS women may seem 
advantageous, the overall disease state is more deleterious than protective. The 
continuous hyperandrogenic and hyperinsulinemia states continue past reproductive years 
and perpetuate the risks associated with them. 
Many of the clinical implications of PCOS become more severe within the post-
menopausal age group, including cancer risk, cardiovascular consequences, and 
metabolic dysfunction. Post-menopausal women are the age group with an increased risk 
of mortality from untreated PCOS's long-term effects. The odds of mortality in females 
with PCOS were 1.66 times higher for Cardiovascular events, including 1.96 for stroke 
and 2.77 for ischemic heart disease (Zhang et al., 2020). A 21-year study followed PCOS 
women through menopause and found significant increases in hypertension and diabetes 
type two, however when controlled for BMI, there was no increase in cancer prevalence 
for uterine, ovarian, or breast cancer (Schmidt, Landin-Wilhelmsen, et al., 2011). Another 
study showed an increase in the risk of ovarian cancer by 2.52 times and endometrial 
cancer by 2.72 times (Chittenden et al., 2009). Breast cancer is strongly correlated with 
obesity and diabetes, and therefore the connection to PCOS is highly debated (Kang et 
al., 2018). Metabolic syndrome increases the aromatase conversion of testosterone to 
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estrogen, increasing pancreatic cancer risk in females with an accompanied 56% 
increased risk of mortality from cancer (Uzunlulu et al., 2016). 
Women with PCOS have two benefits on bone mineral density. First, the 
increased risk of overweight or obese presentation helps build a stronger bone before 
menopause. Increased body mass in adulthood places more mechanical strain on bones 
and can increase bone mineral density (Iwaniec & Turner, 2016). Despite these promising 
features, premenopausal women have lower BMD than their non-PCOS counterparts, 
with hyperandrogenic women having better BMD than PCOS women with normal 
androgen levels (Karadağ et al., 2017).  
Table 5: How Androgen excess in PCOS Affects Bone Remodeling (Taken from Krishnan & 
Muthusami, 2017) 
 
In an animal model with induced hyperandrogenism compared to controls, the 
hyperandrogenic females exhibited decreased glomerular filtration, insulin resistance, 
hyperinsulinemia, and increased BGL compared to their size mated controls (Dalmasso et 




IR, triglycerides, total cholesterol but showed no change in elevated DHT levels in 
animal models (Torres Fernandez et al., 2019). Continued metabolic syndrome during 
menopause increases the risk of CVD and adverse cardiovascular events; however, some 
studies suggest that PCOS risk for metabolic syndrome decreases after menopause 





 The selected treatment method in PCOS depends on the specific presentation of 
the syndrome in each individual and the accompanying physiological disturbances. 
Beginning in adolescence, obesity increases the severity of the presentation of PCOS 
with insulin resistance and oligomenorrhea. Weight loss in obese and overweight PCOS 
women in every age group leads to improved insulin sensitivity, decreased BGL, and 
decreased risk factors. Weight loss also helps to normalize ovulation and increase 
fertility. 
           The most commonly prescribed insulin sensitizer is metformin. Due to the low risk 
associated with metformin and the effectiveness in normalizing BGL and insulin levels, 
metformin is an effective treatment for hyperinsulinemia. The resulting decrease in 
circulating insulin causes a decrease in free circulating androgens. The ability to safely 
combine metformin with other treatments, including COCs, lifestyle modification, and 
other insulin sensitizers, makes it a diverse treatment. Metformin is also used to help 
initiate and maintain pregnancy while decreasing circulating androgens and preventing 
gestational diabetes. Although the immediate fetal and maternal outcomes with 
metformin treatment are positive, further investigation must be performed to investigate 
fetal exposure and long-term metabolic risks to the child.      
           While oral contraceptives may help regulate menstrual cycles and decrease the 
cosmetic effects of PCOS, treatments targeting the metabolic linages of PCOS are more 
effective in normalizing circulating insulin and BGL and showing more improvement in 
menstrual cycle control. Some COCs may increase insulin resistance in PCOS women. 
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The best treatment for androgen excess and insulin resistance is a COC combined with 
SPIOMET. COCs may also help to decrease endometrial and ovarian cancer risk by 
preventing uterine hyperplasia. 
           Incorporating a diet with a low-glycemic index may improve fasting BGL and 
insulin sensitivity better than a traditional hypocaloric diet. Exercise can help to increase 
insulin sensitivity in muscle and benefit psychological disturbances even without weight 
loss. Studies involving lifestyle modifications to diet have high dropout rates in PCOS, 
which may be attributed to weight-controlled increases in post-meal hunger and 
adipokine signaling abnormalities. The largest dropout rates for PCOS studies are found 
in non-white PCOS women with increased rates of dropout correlating with BMI (Kuang 
et al., 2015).  
           PCOS is a significant cause of infertility in reproductive-age females.  A woman's 
ability to predict ovulation may be significantly more difficult due to the unpredictability 
of ovulation. Ovulation induction is typically initiated with clomiphene citrate; however, 
letrozole has shown increased live birth rates and may be a more efficacious choice for 
improving PCOS women's fertility. Also, letrozole has a benefit in increasing 
endometrial proliferation and creating a better site for implantation. Gonadotropins are 
typically avoided since they increase the risk of OHSS in PCOS women. Laparoscopic 
ovarian drilling may decrease androgen levels and temporarily increase fertility. 
When selecting the best course of action for PCOS treatment, the patient's 
fertility, metabolic, and cosmetic goals must be kept in mind. Adolescents may be 
concerned with acne vulgaris and hirsutism, while older women may be concerned with 
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pregnancy. Overall, mitigating metabolic disturbances in PCOS and reducing risk factors 






 The current PCOS management relies heavily on treating the symptoms and 
physiological disturbances once the diagnosis is made. As the prevalence of PCOS in 
American women increases, so does the necessity to recognize and address the root of the 
imbalances. PCOS, when untreated, may increase a female's risk of premature death 
through pathologies including high blood pressure, type 2 diabetes, cancer, and metabolic 
syndrome.   
When diagnosing adolescents, it is essential to note that cycle length 
abnormalities are a common feature of a regular menstrual cycle.  Early in the stages of 
PCOS, adolescents do not fit the Rotterdam criteria for adults if the severity of 
hyperandrogenism or hyperinsulinemia are not as extensive. However, due to the 
predictability of early menstrual irregularities with increased cancer risk and diabetes 
type two, it is crucial to monitor the development of these diseases and instrument 
treatment early. Identifying adolescents that are at an increased risk, monitoring BMI and 
insulin sensitivity, and implementing a low-glycemic diet may prevent the drastic 
increase in androgens and save some women from hirsutism, diabetes type two, and the 
stress of infertility. 
There is currently no definitive treatment for PCOS, and women will have to be 
re-evaluated for changes in their metabolic function throughout their lives. With the 
increased risk for depression, women with PCOS may require additional support through 
therapy to stay motivated on treatment. The addition of cognitive behavioral therapy can 
improve quality of life and potentiate decreases in weight loss and insulin resistance in 
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conjunction with diet and exercise. 
As the prevalence of obesity increases globally, so does the need for early 
identification and better screening of PCOS. Circulating AMH and CXCL14 levels may 
help screen for PCOS. Circulating AMH is currently used to predict ovarian reserve of 
oocytes in females. High AMH levels correspond with increased polycystic ovaries 
confirmed with a transvaginal ultrasound (Lie Fong et al., 2017). AMH levels may help 
to predict polycystic ovaries without the need for an ultrasound in future diagnoses. The 
chemokine CXCL14 has been shown to be low in adolescents with PCOS and SPIOMET 
showed significant improvements in CXCL14 with one year of treatment (García-Beltran 
et al., 2020). 
Potential polymorphisms that lead to PCOS include the StAR transport (which 
regulates cholesterol entry into the mitochondria for steroid synthesis), the GnRH pulse 
generator, the FSH receptor, the FTO gene involved in fat distribution, and many other 
irregularities in metabolic signaling (Y. Chen & Fang, 2018). Additionally, epigenetics 
may play a role in the presentation of PCOS. DNA hypermethylated promoters have been 
observed in PCOS ovaries where the controls showed hypomethylation of the same gene 
(Yu et al., 2015). Another study found that genes involved in steroid and lipid synthesis 
were hypomethylated compared to controls, which may explain metabolic and sex 
hormone abnormalities in PCOS (Pan et al., 2018). In 2014, the hypomethylation of the 
LH/choriogonadotropin receptor was confirmed in PCOS women and therefore increased 




 As BMI continues to increase globally, we will continue to see a rise in 
exacerbated PCOS symptoms. Multidisciplinary care across obstetrics, mental health, and 
endocrinology are required for these patients' complete care. Additionally, identifying the 
etiology or potential multiple causations of PCOS may help create an early and focused 
treatment of the condition and prevent permanent cardiovascular, metabolic, and 
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